3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
147
Thoracic
127
Breast
50
Head & Neck
39
Gynecologic
29
Lymphoid
21
Sarcoma
17
Other hematologic neoplasm
17
CNS
16
Genitourinary
12
Tumor-Agnostic
6
Dermatologic
6
Other solid neoplasm
5
Plasma cell
3
Myeloid
3
Other
2
Classical hematology
2
Endocrine
1
Conditions
Sarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Carcinoma, Neuroendocrine
1
Adrenocortical Carcinoma
1
Interventions
Everolimus
27
pembrolizumab
25
Temozolomide
24
lutetium Lu 177 dotatate
22
Nivolumab
18
Magnetic Resonance Spectroscopy
18
lenvatinib
17
cabozantinib
17
Cisplatin
16
Sunitinib
15
Capecitabine
14
Bevacizumab
14
Specimen Handling
12
Sorafenib
12
trametinib
10
Ipilimumab
10
Etoposide
10
pasireotide
9
dabrafenib
9
Paclitaxel
9
Carboplatin
8
pazopanib
7
lanreotide
7
Octreotide
7
Fluorodeoxyglucose F18
7
anlotinib
6
Irinotecan
6
Injections
6
Doxorubicin
6
surufatinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Drug Therapy
×
Endocrine
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled